Describe diagnostic and prognostic biomarkers and emerging applications for next generation imaging in staging and treatment selection for MIBC, HER-2+ mUC and de novo mHSPC. Evaluate recent clinical trial data and its implications for treatment selection and sequencing in MIBC, HER-2+ mUC and de novo mHSPC. Evaluate the evolving landscape of neoadjuvant treatment in MIBC and de novo mHSPC treatment and the implications for patient care. Implement the most current guideline recommendations and patient-centered care strategies to improve MIBC, mUC and de novo mHSPC diagnosis, treatment, and outcomes
- Provider:HMP Education
- Activity Link: https://hmpeducation.com/program/24onccme115-1
- Start Date: 2025-01-06 06:00:00
- End Date: 2025-01-06 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest